Ó³»­´«Ã½

In a new paper published online by , researchers from Dana-Farber Cancer Institute (DFCI) and the Ó³»­´«Ã½ systematically investigated somatic copy number alterations of noncoding regions across cancers, integrating genomic, epigenomic, and transcriptomic data.

The team found six super-enhancer regions that are focally amplified across different cancer types, including two that are associated with overexpression of the MYC oncogene, suggesting that this type of modification may be a common mechanism activating cancer driver genes. The team, which was led by senior author Matthew Meyerson and first authors Xiaoyang Zhang, Peter Choi, and Joshua Francis – all of Ó³»­´«Ã½ and DFCI – also used genome-editing technologies to validate the oncogenic function of these focally amplified super-enhancers.